HC Wainwright Issues Optimistic Forecast for RIGL Earnings

Key Points

• HC Wainwright significantly raised its Q3 2025 earnings estimate for Rigel Pharmaceuticals to $1.05 per share, an increase from the previous estimate of $0.38.
• Rigel Pharmaceuticals reported earnings of $3.28 per share for the last quarter, surpassing the consensus estimate of $1.97 by $1.31, with a revenue of $101.69 million.
• Cantor Fitzgerald raised its price target for Rigel Pharmaceuticals from $23.00 to $32.00, maintaining a "neutral" rating, while the stock has an average price target of $38.20 according to MarketBeat.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Research analysts at HC Wainwright lifted their Q3 2025 EPS estimates for Rigel Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 6th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $1.05 for the quarter, up from their previous estimate of $0.38. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' Q4 2025 earnings at $1.03 EPS, FY2025 earnings at $5.98 EPS and FY2026 earnings at $5.78 EPS.

Separately, Cantor Fitzgerald increased their price objective on shares of Rigel Pharmaceuticals from $23.00 to $32.00 and gave the stock a "neutral" rating in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $38.20.

Rigel Pharmaceuticals Stock Up 4.1%

Shares of RIGL stock traded up $1.26 during trading hours on Friday, hitting $31.70. 1,373,834 shares of the company were exchanged, compared to its average volume of 376,274. The business has a 50 day moving average of $20.59 and a two-hundred day moving average of $19.99. The company has a current ratio of 2.02, a quick ratio of 2.13 and a debt-to-equity ratio of 0.46. Rigel Pharmaceuticals has a 52 week low of $9.92 and a 52 week high of $32.40. The company has a market capitalization of $568.70 million, a PE ratio of 5.86 and a beta of 1.21.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biotechnology company reported $3.28 earnings per share for the quarter, topping the consensus estimate of $1.97 by $1.31. The company had revenue of $101.69 million for the quarter, compared to analyst estimates of $64.58 million. Rigel Pharmaceuticals had a net margin of 36.51% and a return on equity of 438.89%.

Institutional Investors Weigh In On Rigel Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Rigel Pharmaceuticals by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 1,012,931 shares of the biotechnology company's stock valued at $17,038,000 after purchasing an additional 27,640 shares in the last quarter. Prudential Financial Inc. bought a new position in Rigel Pharmaceuticals in the fourth quarter valued at $197,000. JPMorgan Chase & Co. grew its position in Rigel Pharmaceuticals by 587.9% in the fourth quarter. JPMorgan Chase & Co. now owns 180,492 shares of the biotechnology company's stock valued at $3,036,000 after purchasing an additional 154,254 shares in the last quarter. Norges Bank bought a new position in Rigel Pharmaceuticals in the fourth quarter valued at $2,178,000. Finally, Wellington Management Group LLP bought a new position in Rigel Pharmaceuticals in the fourth quarter valued at $588,000. Institutional investors own 66.23% of the company's stock.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.